Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001083676 | SCV000286960 | benign | Developmental and epileptic encephalopathy 94 | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000245432 | SCV000307174 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Gene |
RCV000245432 | SCV000523405 | benign | not specified | 2016-02-29 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Athena Diagnostics | RCV000711184 | SCV000841515 | benign | not provided | 2018-03-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002315692 | SCV000847640 | likely benign | Inborn genetic diseases | 2016-07-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genetic Services Laboratory, |
RCV000245432 | SCV002071230 | benign | not specified | 2019-04-02 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000711184 | SCV002545317 | benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | CHD2: BP4, BP7, BS1, BS2 |
Fulgent Genetics, |
RCV001083676 | SCV002799015 | likely benign | Developmental and epileptic encephalopathy 94 | 2022-05-23 | criteria provided, single submitter | clinical testing |